Lupin strengthens on entering into definitive distribution agreement with Salix

15 Sep 2014 Evaluate

Lupin is currently trading at Rs. 1371.50, up by 12.25 points or 0.90% from its previous closing of Rs. 1359.25 on the BSE.

The scrip opened at Rs. 1359.00 and has touched a high and low of Rs. 1386.00 and Rs. 1352.70 respectively. So far 43628 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1386.00 on 15-Sep-2014 and a 52 week low of Rs. 833.55 on 18-Sep-2013.

Last one week high and low of the scrip stood at Rs. 1386.00 and Rs. 1307.25 respectively. The current market cap of the company is Rs. 61576.16 crore.

The promoters holding in the company stood at 46.73% while Institutions and Non-Institutions held 42.72% and 10.55% respectively.

Lupin and Salix Pharmaceuticals, Inc. (Salix) have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada. This includes immediate rights to distribute Zaxine (rifaximin) 550 mg tablets for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age or older, and Relistor Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

Additionally, the agreement includes future dosage forms, strengths, and indications for such products. Under the agreement, Lupin also has the option to exclusively market, distribute and sell other gastroenterology products in Salix’s Canadian pipeline once approved by Health Canada.

Lupin will promote the Salix products through its own sales force in Canada. Lupin is in the process of establishing its Canadian presence and the addition of this significant product portfolio opens up growth opportunities for the future. Zaxine and Relistor are First-in-Class Treatments for their respective disorders and are important treatment options for physicians and their patients, not only in the US, but now in Canada.

Under the terms of the Agreement, Salix will receive an upfront payment and distribution fees, and is eligible for additional pre-commercial and sales milestone payments. Salix will supply the products to Lupin under separate supply agreements.

Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×